このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

The Use of Virtual Reality for Lumbar Pain Management in an Outpatient Spine Clinic

2021年2月22日 更新者:David Saul Binder、Spaulding Rehabilitation Hospital

The Use of Virtual Reality for Lumbar Pain Management in an Outpatient Spine Clinic: An Exploratory Comparative Randomized Trial

The management of chronic pain is a significant public health issue related to escalating treatment costs, lost productivity, disability and medication use. The prevalence of chronic pain is rising alarmingly across all subpopulations with chronic low back pain (LBP) being labeled as one of the 15 most expensive medical conditions. Both study investigators are involved in the medical treatment of these patients. The investigators are interested in testing the effectiveness of alternative treatment strategies that address the complexity of chronic pain that is often mediated not only by physiologic variables, but also psychosocial issues. There is emerging evidence that Virtual Reality (VR) may be an effective pain management tool to augment care in this population, reducing medical costs, decreasing medication use, improving outcomes and empowering patients to take more control over their own health and management of chronic pain. Less is known about the use of this technology delivered in the context of care delivered in an outpatient clinical setting.

調査の概要

詳細な説明

The investigators propose to conduct a comparative randomized trial of 45 patients who will be recruited during their office visit at the Spaulding Rehabilitation Hospital Outpatient Center in Cambridge and/or the Massachusetts General Hospital (MGH) Spine Center in Boston. All patients with chronic LBP who elect to receive a spinal injection will be eligible to be screened for inclusion and exclusion criteria. Prior to the injection appointment in Charlestown, Massachusetts, chronic lumbar pain patients are seen by the interventional physiatrist for an examination and discussion of pain management care options. If the patient and MD determine that a spinal injection is indicated, and the patient meets the inclusion criteria, the medical assistant will hand the patient an informational flyer describing study procedures and briefly describe the study. As the study poses minimal risks and low patient time burden beyond the context of standard clinical care, the patient will indicate their wiliness to participate at the end of this clinic visit.

The patient's status will be registered in Epic and will be viewable by authorized study staff. If a consented study participant is active on gateway, the Epic Patient Reported Outcome Information System (PROMIS) measures identified could be administered via the Epic patient portal or they could be administered via iPad as per usual procedures at the injection clinic appointment in Charlestown. Upon arrival to the injection appointment in Charlestown, front desk personnel will hand study participants (flagged in the Epic record) additional paper questionnaires that are not included in the Patient Reported Outcome Measures (PROMs) PROMIS questionnaire battery but are recommended by the National Institute of Health (NIH) task force on research on chronic LBP patients or otherwise identified by the co-investigators as important to address the study aims. If the patient is not active on gateway, an iPad will be used to collect the PROMs PROMIS Epic measures upon clinic arrival. Once all measures have been collected, patients will be randomized using a computer-generated schedule that will randomly assign participants into either the control, computer delivered audiovisual intervention (AV), or the virtual reality (VR) delivered intervention.

Those patients randomized into the control group will receive usual care. After the injection, the control group will receive the anxiety measure and the pain intensity measure. These will be administered in paper format and collected by authorized study personnel. This will conclude study participation.

Study participants randomized into the audiovisual (AV) intervention group will watch and listen to a 5-minute guided relaxation session on a computer in the pre-procedure examination room prior to the injection. The injection is not part of the study procedures and is performed in a separate fluoroscopy suite. Authorized study personnel will be present in the clinic on injection days. Clinic personnel will notify study staff of the patient's randomized status. Study staff will enter the injection preparation room and make sure the patient is comfortably seated. Study staff will launch the 5-minute audiovisual presentation on a computer and leave the room. Clinic personnel will enter after the presentation is concluded and continue with standard clinic preparation for the injection. The presentation is commercially available by Provata Health. No data will be collected or identifying information provided in this process. After receiving the injection and returning to the preparation exam room, study staff will facilitate completion of the anxiety thermometer, the pain intensity measures, and a single response measure that asks if they would be interested in viewing the same presentation on their home computers. This will conclude study participation.

Those study participants randomized into the VR group will watch and listen to the same 5-minute presentation via a VR headset and smart phone. Once a study participant's status has been randomized into the VR group, study staff will enter the injection preparation room, ensure the participant is comfortably seated, orient the participant to the device, apply the headset on the participant to ensure comfort and launch the VR 5-minute presentation. Study staff will then exit the room. No data will be collected or identifying information provided during this process. The Samsung Galaxy 7s and the Samsung adaptable VR headset will be used to deliver the intervention. Clinic staff will enter the room after the 5-minute VR presentation and continue with standard clinic pre-injection procedures. After the injection and upon return to the preparation room, study staff will facilitate administration of the anxiety thermometer measure, the pain intensity measure, the virtual reality symptom questionnaire that addresses 13 symptoms that people who view VR delivered content may experience, and a single response question that asks if they would be interested in viewing the VR content on their own at home. This will conclude study participation.

The VR headset will utilize a disposable cloth face barrier and will be thoroughly cleaned with alcohol solution between patient use. A disposable hygienic face barrier will be applied to all areas of possible direct patient contact of the VR headset. This barrier is held in place by cloth straps, is hypoallergenic, and only surrounds the eyes (therefore will not affect vision or respiration). Provata health produces content that can be delivered through VR or regular delivery via a computer screen (AV). By delivering identical content in two different ways, the investigators will be able to determine if the method of delivery provides any specific advantages or disadvantages. The investigators will also be able to compare outcomes with those who received usual care.

研究の種類

介入

入学 (実際)

45

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Massachusetts
      • Boston、Massachusetts、アメリカ、02114
        • Massachusetts General Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Patients attending an appointment to receive a lumbar spinal injection.
  2. Patients meeting the definition of chronic LBP as established by the NIH task force: Back pain problem that has persisted at least 3 months, and has resulted in pain on at least half the days in the past 6 months

Exclusion Criteria:

  1. Age younger than 18 years
  2. Not being fluent and literate in English
  3. Patients receiving injections in areas other than the lumbar or pelvic region

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
介入なし:Control

15 participants will be randomly assigned to the control group. They will receive no intervention other than the injection (which is not a part of the trial).

Pre-injection they will receive all baseline measures and questionnaires. Post injection they will receive the primary outcome measures: 1) Numeric Pain Rating Scale and 2) Anxiety thermometer

アクティブコンパレータ:Audiovisual (AV) Guided Relaxation
Combination Product: Audiovisual Guided Relaxation Five-minute guided relaxation delivered via a computer screen and speakers
Five-minute guided relaxation delivered via a computer screen and speakers
実験的:Virtual Reality (VR) Guided Relaxation

Combination Product: Virtual Reality Guided Relaxation Five-minute guided relaxation delivered via a Samsung Galaxy 7s and the Samsung adaptable VR headset.

Other Names:

• Samsung Galaxy 7s/Samsung adaptable VR headset

Five-minute guided relaxation delivered via a Samsung Galaxy 7s and the Samsung adaptable VR headset.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change is being assessed between two time points by The Numeric Pain Rating Scale
時間枠:First time point: At the beginning of the injection clinic visit, prior to receiving the injection. Second time point: approximately 1 hour later, at the conclusion of the injection clinic visit, after receiving the injection
Self-report current pain rating on a 0-10 scale with 0 being no pain and 10 being the worst pain imaginable
First time point: At the beginning of the injection clinic visit, prior to receiving the injection. Second time point: approximately 1 hour later, at the conclusion of the injection clinic visit, after receiving the injection

二次結果の測定

結果測定
メジャーの説明
時間枠
Change is being assessed between two time points by The Anxiety Thermometer
時間枠:First time point: At the beginning of the injection clinic visit, prior to receiving the injection. Second time point: approximately 1 hour later, at the conclusion of the injection clinic visit, after receiving the injection
a visual numeric rating scale of current anxiety level from 0-10 with 0 being not at all anxious up to 10 being extremely anxious
First time point: At the beginning of the injection clinic visit, prior to receiving the injection. Second time point: approximately 1 hour later, at the conclusion of the injection clinic visit, after receiving the injection
Virtual Reality Symptom Questionnaire
時間枠:Measured at one time point approximately 1 hour from the time of randomization
This is a self report measure related to symptoms encountered when viewing virtual reality content. This questionnaire will only be administered to the participants randomized into the virtual reality group. Description: 13 symptoms are rated from 0-6 with 0 being no symptoms; 1-2=slight; 3-4=moderate; 5-6=severe; the 13 categories are: general discomfort, fatigue, boredom, drowsiness, headache, dizziness, difficulty concentrating, nausea, sore/aching eyes, tired eyes, eye strain, blurred vision, difficulty focusing; scored as a sum of all categories
Measured at one time point approximately 1 hour from the time of randomization

その他の成果指標

結果測定
メジャーの説明
時間枠
Interest questions about the guided relaxation content
時間枠:Measured at one time point approximately 1 hour from the time of randomization

This questionnaire will be administered to those participants randomized into the audiovisual and the virtual reality groups. 1. Would you be interested in having the guided relaxation video to view:

i. On your computer at home? ii. On a VR headset at home? 2. Do you feel this type of guided relaxation might be useful in helping you manage your pain?

Measured at one time point approximately 1 hour from the time of randomization

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:David S Binder, MD、Spaulding Rehabilitation Hospital

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2019年4月8日

一次修了 (実際)

2019年7月9日

研究の完了 (実際)

2019年9月1日

試験登録日

最初に提出

2019年1月17日

QC基準を満たした最初の提出物

2019年1月24日

最初の投稿 (実際)

2019年1月29日

学習記録の更新

投稿された最後の更新 (実際)

2021年2月23日

QC基準を満たした最後の更新が送信されました

2021年2月22日

最終確認日

2021年2月1日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

  • 2018P003042Final

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する